Skip to contentSkip to filters

We use cookies for analytics.

Part the Cloud: Enable the Molecule for AI-Discovered Programs — 2027 Funding

Medicinal Chemistry, Neuropharmacology, Clinical Neurology and research grant from Alzheimer’s Association

Closed on Tuesday, Oct 20

Up to $1,000,000
View call page (opens in a new tab)

About

Funds experimental advancement of AI-discovered therapeutic leads for Alzheimer’s disease and related dementias. Separate tracks support lead optimization and work enabling an investigational-new-drug submission. Awards are up to USD 1 million over two to three years. Pure algorithm development, general AI platforms, repurposing and clinical trial execution are excluded. Letters of intent are due 20 October 2026 at 17:00 Eastern time (22 October for ISTAART members); invited full applications follow on 15 December (17 December for members).

Eligibility

Career stage: Early independent researcher · Mid-career researcher · Established researcher

Institution applies

Covers: Up to USD 1 million total over two to three years.

Host location: Worldwide

International applicants, including eligible Austrian and European institutions; programme exclusions apply.

Eligibility sourceSource 2

Reviewed Sep 24, 2026. Check the funder’s full conditions before applying.

Full-time investigators at Assistant Professor level or equivalent and above; students and postdocs cannot be lead applicants. Eligible international institutions may apply, subject to programme and sanctions rules. Only one proposal per applicant across the current competition; reporting and institutional exclusions apply.

Topics

Alzheimer’s diseaserelated dementiasAI-discovered therapeutic leadslead optimizationinvestigational-new-drug submissionexperimental advancementISTAART

Related funding

Open funding in Medicinal Chemistry

All funding

Source: alz.org